[go: up one dir, main page]

BRPI0409721A - compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos - Google Patents

compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos

Info

Publication number
BRPI0409721A
BRPI0409721A BRPI0409721-1A BRPI0409721A BRPI0409721A BR PI0409721 A BRPI0409721 A BR PI0409721A BR PI0409721 A BRPI0409721 A BR PI0409721A BR PI0409721 A BRPI0409721 A BR PI0409721A
Authority
BR
Brazil
Prior art keywords
compounds
isoxazole
treatment
neurodegenerative disorders
formula
Prior art date
Application number
BRPI0409721-1A
Other languages
English (en)
Inventor
Yuhpyng Liang Chen
Lei Zhang
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BRPI0409721A publication Critical patent/BRPI0409721A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMPOSTOS DE ISOXAZOL E ISOTIAZOL PARA O TRATAMENTO DE DISTúRBIOS NEURODEGENERATIVOS". A presente invenção refere-se a compostos de Fórmula I, em que R¬ 3¬, R¬ 5¬, R¬ 6¬, R¬ 7¬ X, Y e Z são como definidos. Os compostos de Fórmula I possuem atividade 5 de inibição da produção de peptídeo A<225>. Esta invenção refere-se também a composições farmacêuticas e métodos de tratamento de doenças, por exemplo, doenças neurodegenerativos, por exemplo, doença de Alzheimer, em um mamífero, compreendendo compostos de Fórmula I.
BRPI0409721-1A 2003-05-12 2004-05-10 compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos BRPI0409721A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47000203P 2003-05-12 2003-05-12
PCT/IB2004/001478 WO2004099200A1 (en) 2003-05-12 2004-05-10 Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders

Publications (1)

Publication Number Publication Date
BRPI0409721A true BRPI0409721A (pt) 2006-05-02

Family

ID=33435258

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409721-1A BRPI0409721A (pt) 2003-05-12 2004-05-10 compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos

Country Status (7)

Country Link
US (1) US7241786B2 (pt)
EP (1) EP1636220A1 (pt)
JP (1) JP2006525990A (pt)
BR (1) BRPI0409721A (pt)
CA (1) CA2524511A1 (pt)
MX (1) MXPA05012196A (pt)
WO (1) WO2004099200A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
ATE399155T1 (de) * 2004-03-23 2008-07-15 Pfizer Prod Inc Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
US7220865B2 (en) * 2004-04-01 2007-05-22 Pfizer Inc Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders
US7244757B2 (en) * 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
EA200800659A1 (ru) * 2005-09-22 2008-08-29 Пфайзер Продактс Инк. Соединения имидазола для лечения неврологических нарушений
US7935715B2 (en) 2006-07-28 2011-05-03 Boehringer Ingelheim International Gmbh Compounds which modulate the CB2 receptor
MX2009002888A (es) 2006-09-25 2009-03-31 Boehringer Ingelheim Int Compuestos que modulan el receptor cb2.
CA2704684A1 (en) 2007-11-07 2009-05-14 Boehringer Ingelheim International Gmbh Compounds which modulate the cb2 receptor
CA2716515A1 (en) 2008-02-21 2009-08-27 Boehringer Ingelheim International Gmbh Amine and ether compounds which modulate the cb2 receptor
CA2730037A1 (en) 2008-07-10 2010-01-14 Boehringer Ingelheim International Gmbh Sulfone compounds which modulate the cb2 receptor
PE20110397A1 (es) 2008-09-25 2011-07-01 Boehringer Ingelheim Int Compuestos que modulan selectivamente el receptor cb2
WO2010096371A2 (en) 2009-02-18 2010-08-26 Boehringer Ingelheim International Gmbh Heterocyclic compounds which modulate the cb2 receptor
US8299103B2 (en) 2009-06-15 2012-10-30 Boehringer Ingelheim International Gmbh Compounds which selectively modulate the CB2 receptor
JP5756800B2 (ja) 2009-06-16 2015-07-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｃｂ２受容体を調節するアゼチジン２−カルボキサミド誘導体
EP2480544A1 (en) 2009-09-22 2012-08-01 Boehringer Ingelheim International GmbH Compounds which selectively modulate the cb2 receptor
EP2523936A1 (en) 2010-01-15 2012-11-21 Boehringer Ingelheim International GmbH Compounds which modulate the cb2 receptor
US8329735B2 (en) 2010-03-05 2012-12-11 Boehringer Ingelheim International Gmbh Tetrazole compounds which selectively modulate the CB2 receptor
WO2012012307A1 (en) 2010-07-22 2012-01-26 Boehringer Ingelheim International Gmbh Sulfonyl compounds which modulate the cb2 rece
AR091516A1 (es) 2012-06-22 2015-02-11 Actelion Pharmaceuticals Ltd Derivados de 1-[m-carboxamido(hetero)aril-metil]-heterociclil-carboxamida
EP2803668A1 (en) 2013-05-17 2014-11-19 Boehringer Ingelheim International Gmbh Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles
GB201820166D0 (en) * 2018-12-11 2019-01-23 Ucb Biopharma Sprl Therapeutic agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0586537A4 (en) * 1991-05-28 1997-06-25 Merck & Co Inc Substituted n-carboxyalkylpeptidyl derivatives as antidegenerative active agents
PL178766B1 (pl) * 1992-12-16 2000-06-30 Basf Ag Nowe peptydy
WO2000024392A1 (en) * 1998-10-26 2000-05-04 Sumitomo Pharmaceuticals Company, Limited β-AMYLOID FORMATION INHIBITORS
AR039059A1 (es) * 2001-08-06 2005-02-09 Sanofi Aventis Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios
WO2003064396A1 (en) * 2002-02-01 2003-08-07 Elan Pharmaceuticals, Inc. Hydroxyalkanoyl aminopyrazoles and related compounds
CN1688557A (zh) * 2002-10-09 2005-10-26 辉瑞产品公司 用于治疗神经变性疾病的噻唑化合物
JP2006504725A (ja) * 2002-10-09 2006-02-09 ファイザー・プロダクツ・インク 神経変性障害治療用ピラゾール化合物

Also Published As

Publication number Publication date
MXPA05012196A (es) 2006-02-08
WO2004099200A1 (en) 2004-11-18
CA2524511A1 (en) 2004-11-18
US20040242666A1 (en) 2004-12-02
JP2006525990A (ja) 2006-11-16
EP1636220A1 (en) 2006-03-22
US7241786B2 (en) 2007-07-10

Similar Documents

Publication Publication Date Title
BRPI0409721A (pt) compostos de isoxazol e isotiazol para o tratamento de distúrbios neurodegenerativos
BR0314611A (pt) Compostos de tiazol para o tratamento de distúrbios neurodegenerativos
BRPI0413709A (pt) compostos para o tratamento de distúrbios neurodegenerativos
BRPI0413245A (pt) compostos heteroarila de 6 membros para o tratamento de distúrbio neurodegenerativos
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
BRPI0509069A (pt) compostos de imidazol para o tratamento de distúrbios neurodegenerativos
BR112012015714A2 (pt) composto, composição farmacêutica, método para o tratamento de uma doença neurodegenerativa, método para reduzir a concentração de p-ser-alfa-sinucleina em tecido cerebral, e, método para o tratamento de um câncer
BRPI0911874A2 (pt) composições combinadas para o tratamento da doença de alzheimer e doenças relacionadas com zonisamida e acamprosato
BRPI0713755A8 (pt) composto ou um sal ou solvato do mesmo, uso do composto ou um sal ou salvato do mesmo, composição farmacêutica,e, processo para a preparação de um composto ou um sal ou solvato do mesmo
BRPI0415683A (pt) inibidores da reabsorção de norepinefrina para o tratamento de distúrbios do sistema nervoso central
BR0306724A (pt) carboxamidas amino substituìdas para tratamento de doença de alzheimer
ATE371724T1 (de) Behandlung neurodegenerativer krankheiten
BRPI0509504A (pt) compostos de tiadiazol-amina para o tratamento de distúrbios neurodegenerativos
BRPI0413349A (pt) compostos de oxazol para o tratamento de doenças neurodegenerativas
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
ECSP088280A (es) Compuestos de imidazol para el tratamiento de trastornos neurológicos
BRPI0509464A (pt) compostos tiazol sulfonamida para o tratamento de distúrbios neurodegenerativos
BRPI0509559A (pt) compostos de pirazolamina para o tratamento de distúrbios neurodegenerativos
BRPI0513647A (pt) derivados de ácidos 1-fenilalcanocarboxìlicos para o tratamento de doenças neurodegenerativas
BRPI0509386A (pt) compostos de isoxazol- e isotiazol-amina para o tratamento de distúrbios neurodegenerativos
BRPI0509582A (pt) compostos de tiazol-amina e respectivas composições farmacêuticas
BRPI0704074B8 (pt) derivados piperidínicos da (-)-cassina e (-)-spectalina, composições farmacêuticas contendo os mesmos e processos para sua preparação
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
DOP2004000982A (es) Compuestos para el tratamiento de trastornos neurodegenerativos
DOP2006000200A (es) Compuestos de imidazol para el tratamiento de trastonos neurologicos

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.